Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/25—Silicon; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/41—Amines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q15/00—Anti-perspirants or body deodorants
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
  • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
  • B65D83/00—Containers or packages with special means for dispensing contents
  • B65D83/14—Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant for a product delivered by a propellant
  • B65D83/68—Dispensing two or more contents, e.g. sequential dispensing or simultaneous dispensing of two or more products without mixing them
  • B65D83/682—Dispensing two or more contents, e.g. sequential dispensing or simultaneous dispensing of two or more products without mixing them the products being first separated, but finally mixed, e.g. in a dispensing head
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
  • A61K2800/30—Characterized by the absence of a particular group of ingredients
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/87—Application Devices; Containers; Packaging
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/88—Two- or multipart kits
  • A61K2800/882—Mixing prior to application

Definitions

• the present invention relates to a cosmetic for reducing or preventing apoekkrinen sweat formation from a packaging with two pantries and two cosmetic part preparations, characterized in that a chamber
• secreted aqueous secretion There are three types of sweat glands in the skin, namely, apocrine, eccrine, and apoekrine sweat glands (Int J Cosmet Sei. 2007 Jun;
• the eccrine sweat glands in humans are distributed practically throughout the body and can produce significant amounts of a clear, odorless secretion that is over 99% water.
• the apocrine sweat glands occur only in the hairy body areas of the armpit and genital region and on the nipples. They produce small amounts of a milky secretion that contains proteins and lipids and is chemically neutral.
• Sweating also known as transpiration, is an effective mechanism to release excess heat and thereby regulate body temperature.
• the volume-rich aqueous secretion of the eccrine glands which can produce up to 2-4 liters per hour or 10-14 liters a day in adults, is used for this purpose.
• the sweat - especially the secretion of apocrine sweat glands - is also signaled by the sense of smell. In humans, the apocrine sweat plays in particular in connection with the emotional or stress related
• Cosmetic antiperspirants or deodorants / deodorants are used to eliminate body odor or to reduce their formation.
• Body odor arises when the per se odorless fresh sweat by microorganisms such. Staphylococci and
• Deodorant and "antiperspirant”. Rather, especially in the German-speaking Space - products for use in the underarm area generally referred to as deodorants or "deodorants.” This is irrelevant to the question of whether an antiperspirant effect is present.
• Antiperspirants are antiperspirants that - in contrast to the
• Deodorants which generally prevent microbial decomposition of already formed sweat - to prevent the secretion of sweat at all.
• non-colloidal silver also shows odor neutralization (masking), influencing of bacterial metabolisms, the pure perfuming as well as the use of precursors of certain perfume components, which are converted by enzymatic reactions to fragrant substances.
• Sweat odor consists to a large extent of branched-chain fatty acids, which are released by bacterial enzymes from odorless sweat.
• Classic deodorizing agents counteract this by reducing the growth of bacteria.
• the substances used for this purpose also act nonselectively against useful skin germs and can lead to skin irritations in sensitive individuals.
• the classic antiperspirants used are, in particular, aluminum salts or aluminum / zirconium salts. These inhibit the flow of sweat by obstructing the excretory ducts of the sweat glands by precipitating them together with the skin's own proteins and thus leading to so-called plugs. Therefore, there may be a congestion of sweat within the gland.
• Corneocytes in the sweat gland duct (Shelley WB and Hurley HJ, Acta, Derm. Venereol. (1975) 55: 241-60), or by the emergence of an ACH / AZG gel (Reiler HH and Luedders WL, in: Advances in Modern Hemisphere Publishing Company, Washington and London. Toxicology, Dermatoxicology and Pharmacology, FN Marzulli and HI Maibach, Eds (1977) Vol. 4: 1-5) formed by neutralization in the sweat gland duct is still open.
• such aluminum salts as aluminum hydroxychlorides can cause skin damage if used frequently and on sensitive persons.
• the use of the aluminum salts can cause discoloration of textiles which come into contact with the antiperspirant.
• antiperspirants and deodorants (Deo) are offered in a variety of product forms, with scooters, pump sprayers and aerosols dominating in Europe, and deodorant sticks ("sticks") in the US, Central and South America. Both anhydrous (suspensions) and water-containing products (hydro-alcoholic formulations, emulsions) are known.
• a satisfactory deodorant means the following conditions are met: 1)
• liquid deodorants and antiperspirants Apart from the liquid deodorants and antiperspirants, solid preparations, for example powders, powder sprays, are also known and customary as intimate cleaners.
• the nature of the composition of cosmetic preparations finds its natural limits, due to the compatibility of the individual components with each other and the stability of
• FR 2852928 discloses a two-chamber container in which the product is removed by means of two pumps in such a way that the preparations are mixed only in the output channel. From US 20040149775 a two-chamber container in which the chambers are interchangeable are known. Again, the output of the preparations by means of two pumps via a common output channel in which the mixing of the components takes place.
• EP 958062 discloses a dual chamber packing means with concentrically arranged pumps.
• EP 0461010 discloses a two-chamber aerosol canister in which the mixture of the
• a disadvantage of the aluminum salts used hitherto for sweat inhibition is the currently not yet fully understood long-term toxicity.
• Aluminum has been suspected for a long time neurodegenerative diseases such as dementia, in particular Alzheimer's, to promote or trigger. Also, aluminum is associated with the development of breast cancer. So far, there is no verified evidence that works over the skin
• Al salts are short-chain silicates in the form of silicic acids, which can reliably suppress sweat formation.
• Silica acids are the oxygen acids of silicon. The easiest
• Polymers are sometimes referred to as meta-silicic acid (H2S1O3, [-Si (OH) 2-0-] n ). If these low-molecular-weight silicic acids continue to condense, amorphous colloids (silica sol) are formed.
• the general empirical formula of all silicas is H2n + 2Si n 03n + i.
• the empirical formula is often S1O2 ⁇ n H2O; However, the water is not with silicas
• Silica the anhydride of silicic acid.
• the salts of acids are called silicates.
• silicic acid esters are Technically used or prepared alkali metal salts.
• the esters of silicic acids are called silicic acid esters.
• NPK low molecular weight polysilicic acids
• the silicas prepared by this method are stable only at these very low pH levels. From a pH of 3.5 condensation occurs, which is noticeable by precipitation gelation. These precipitates of high molecular weight silicic acids no longer have an AT effect.
• NPK non-semiconductor phosphatidylcholine
• pH values below 3.5 are physiologically incompatible, formulations must be found in which the pH is at least 3.5 and in which there is no gelation or precipitation of amorphous colloids (silica sol).
• a further object of the present invention was thus to develop a product which is suitable as the basis for cosmetic deodorants or antiperspirants and which does not have the disadvantages of the prior art, in particular is distinguished by good skin tolerance.
• the object of the invention is, in particular, siliceous antiperspirant preparations containing low molecular weight polysilicic acids (NPK) in combination with one or more to provide stabilizers available, with sufficient stability have a physiologically acceptable pH.
• NPK low molecular weight polysilicic acids
• Preparations with a pH of at least 3.5, containing NPK and one or more stabilizers for use as hypoallergenic antiperspirants, ie for reducing or preventing apoekkrinen sweat formation, are suitable if the pH increase takes place shortly before the application and thereby the disadvantages of Prior art, the lack of stability of physiologically acceptable NPK preparations, is eliminated.
• the invention is therefore a cosmetic product comprising a two-chamber container suitable for the application of cosmetic preparations, characterized in that a chamber contains a partial preparation containing low molecular weight, highly amorphous silica (NPK) in combination with one or more stabilizers (phase 1) and the second chamber contains a preparation containing at least one base (phase 2), wherein in the application, the contents of the first and second chambers are simultaneously removed from the chambers and mix the phases 1 and 2 at the issue or shortly before the issue.
• NPK highly amorphous silica
• the invention encompasses the use of NPK, as an antiperspirant active, preferably in topically administrable, in particular cosmetic and / or dermatological, preparations, wherein the pH of the preparation only before application to a
• physiologically acceptable level is set, in particular the pH of the applied preparation is not less than 3.5.
• the stabilizers are selected from group A: Hexenol ice 3 (CAS 928-96-1), terpineol (CAS 8000-41 -7), linalool (CAS 78-70-6),
• Tetrahydrolinalool (CAS 78-69-3), triethyl citrate (CAS 77-93-0), 2-isobutyl-4-hydroxy-4-methyltetrahydropyran (CAS 63500-71-0), hexyl salicylate (CAS 6259-76-3 ), Phenylethyl alcohol (CAS 60-12-8), 3-methyl-5-phenyl-1-pentanol (CAS 55066-48-3), 2,6-dimethyl-7-octene-2-o (CAS 18479 -58-8), benzyl salicylate (CAS 1 18-58-1), geraniol (CAS 106-24-1), citronellol (CAS 106-22-9) and ethyllinalool (CAS 10339-55-6); group B: alcohols and diols and group C: substances with at least three hydroxyl groups.
• Particularly advantageous group B stabilizers are: ethanol, 2-propanol, PEG 8, triethylene glycol, methylphenylbutanol, decanediol, polyglyceryl-2-caprate, oxalic acid.
• Particularly advantageous stabilizers from group C are: sucrose (mannose, mannitol), glycerol, pentaerythritol, threitol, erythritol, hyaluronic acid.
• the topical application of preparations - ie the use of cosmetic or dermatological preparations on the skin - containing NPK in combination with one or more stabilizers chosen from the group A, B and / or C allows the reduction or prevention of stress sweating.
• NPK act as a sweat inhibitor and reduce the formation of sweat and thus indirectly also the smell of sweat.
• preparations which have a high physiological compatibility.
• the mixture of NPK-containing preparation with the pH-increasing base only before the application of a two-chamber packaging makes the use of NPK-containing preparations as a compatible antiperspirant only possible.
• Products according to the invention with NPK allow an antiperspirant effect on the order of known and proven antiperspirant active ingredients, wherein the required concentration of NPK is much lower than when using ACH.
• the pH increase only before the application also leads to the elimination of the disadvantages listed, such as skin irritation due to too low pH of unstabilized silicas and the toxicity of aluminum compounds under discussion.
• products according to the invention preferably comprise, in addition to an NPK-containing preparation, no further antiperspirant substances or preparations, in particular none
• Aluminum salts in particular no ACH and / or AACH (activated aluminum chlorohydrate).
• An essential advantage of the products according to the invention is, moreover, that no discoloration on the skin or clothing is evident as compared with the AT agents based on aluminum salts. The so-called whiteness as well as those after repeated wearing and washing in textiles resting directly on the underarm skin are not observed
• the stabilized silicas can be incorporated in a simple manner into the compositions suitable for products according to the invention. They are preferably added as NPK solution to the other constituents of the formulations. The proportion of NPK solution can make up to 98% of the total amount of the formulation. in the
• a thickener and a perfume are added to the NPK suspension, perfume meaning a mixture comprising one or more olfactorily detectable individual substances.
• Silica acids stabilized for use according to the invention can be e.g. Produce according to the following methods on a laboratory scale:
• step 2 for pH reduction are particularly suitable.
• pH reduction can also be carried out any other acids, as long as these a) the pH value accordingly and b) their salts, in particular sodium salt, are physiologically compatible or do not cause any skin irritation. Preference is given to pH reduction
• the fast pH reduction is crucial for the successful formation of the NPK. If the pH reduction is too slow, form very high molecular weight silica, which have no antiperspirant activity, to gelation.
• Increasing the pH in step 3 to a cosmetically acceptable level is optional and can be accomplished with caustic soda, caustic potash, or with weaker bases.
• Useful bases include: 2-aminobutanol, 2- (2-aminoethoxy) ethanol, aminoethyl propanediol, aminomethyl propanediol, aminomethyl propanol, aminopropanediol, bis-
• Isopropanolamines methyl diethanolamines, methylethanolamines, triethanolamines,
• Triisopropanolamines Triisopropanolamines, tromethamines, polyethylenimines, tetrahydroxypropylethylenediamine, ammonia.
• the increase in pH can also be carried out with buffer systems, which is also considered in the context of the invention as a base, which are added either in aqueous solution or anhydrous.
• the buffer systems can consist of the abovementioned bases and cosmetically acceptable acids and have a pH of from 3 to 11, preferably from 7 to 9.
• Alkali hydroxides whose cations are physiologically compatible and easy to keep in solution.
• sodium and / or potassium hydroxide solution are suitable for raising the pH.
• the pH increase can be advantageously carried out in stages, with a more concentrated base, e.g. 5N NaOH, and only to adjust the final pH, a less concentrated base, e.g. 0.5N NaOH, is used. It is advantageous to first bring the pH to pH 2 with 5N NaOH and then further increase to at least pH 3.5 with 0.5N NaOH.
• Particularly suitable stabilizers for this preparation method are ethanol, glycerol, 2-propanol, PEG 8, triethylene glycol, urea, oxalic acid, hyaluronic acid, ethylhexylglycerol, pentaerythritol, threitol, erythritol, methylphenylbutanol, polyglyceryl 2-caprate, decanediol
• Particularly preferred is a use of glycerol and ethanol in a ratio of 1:10 to 6:10, in particular 5 to 30 wt .-% glycerol and 30 wt .-% EtOH based on the total amount of sodium silicate solution prepared in step 1.
• step 3 The same conditions apply to the pH reduction (step 3) and the pH increase (step 4) as to step 2 and step 3 of method I.
• Suitable stabilizers for this stabilized NPK preparation process are sucrose, mannose and / or mannitol.
• step 2 The same conditions apply to the pH reduction (step 2) and the pH increase (step 3) as to step 2 and step 3 of method I.
• Suitable stabilizers for this stabilized NPK preparation process is glycerol.
• the pH increase with 0.1 to 0.5 M sodium hydroxide in glycerol is advantageous, as this possible, pH peaks' can be prevented.
• step 2 (method I and III) and step 3 (method II) by combining the reactants
• the cosmetic products according to the invention containing in a chamber a stabilized NPK preparation, in the form of aerosols, so from
• a good method is also the spreading or rubbing by means of flat applicators, which are fed by a two-chamber container, in particular applicators with flocked and / or textile surface, since they have a low tendency to clog.
• Preferred application form for the antiperspirants with stabilized NPK are water-containing aerosols. It is advantageous with respect to aluminum chlorohydrate-containing AT sprays that the stabilized NPK is present dissolved in the preparation and does not have to be resuspended by shaking before using the spray. The clogging probability of the nozzles is thereby reduced. Furthermore, a use of stabilized NPK in two-chamber roll-ons and
• pump sprays offer a contactless application of the AT preparation to the skin.
• pressure-resistant containers can be dispensed with.
• Two-chamber pump sprays can be made metal-free, in particular aluminum-free.
• containers made of PE, PP or PET which are closed with one or two metal-free spray pump (s), wherein metal-free means that the pumped preparation does not come into contact with metallic components.
• metal-free means that the pumped preparation does not come into contact with metallic components.
• the feed takes place via one or two risers and the mixture of the NPK-containing preparation (phase 1) with the base (phase 2) takes place before or after the pump (s) ,
• the stabilized NPK (Phase 1) are in the inventive
• Antiperspirant formulations preferably in an amount of 0, 1 to 10 wt .-%, content of NPK based on the total mass of the preparation, i. including the possibly existing propellants used. Particularly advantageous are concentrations of 0.5 to 3 wt .-%.
• the proportion of one or more stabilizers in phase 1 can advantageously be selected up to 85% by weight, in particular up to 30% by weight, based on the total mass of the preparation.
• the proportion of SiO 2 equivalents in phase 1 is advantageously in the range of 0.1. Up to 6 wt .-%, preferably 0.5 to 3 wt .-%, based on the total mass of the preparation selected.
• the proportion of one or more stabilizers in phase 1 can advantageously be selected up to 85% by weight, in particular up to 30% by weight, based on the total mass of the preparation.
• the proportion of NPK in phase 1 is advantageously in the range of 0, 1 to 6 wt .-%, preferably 0.5 to 3 wt .-%, based on the total mass of the preparation chosen.
• the preparations containing stabilized NPK (phase 1) or the base (phase 2) contain cosmetic auxiliaries as are customarily used in such preparations, e.g. Preservatives, preservatives,
• Bactericides perfumes, UV filters, antioxidants, water-soluble vitamins, minerals, suspended solid particles, foaming inhibitors, dyes, pigments having a coloring effect, thickeners, moisturizing and / or moisturizing substances or other common ingredients of a cosmetic or dermatological Formulation such as electrolytes, organic solvents, alcohols, polyols, emulsifiers, polymers, foam stabilizers or silicone derivatives.
• the preparations are preferably produced and used in an optically appealing transparent manner.
• Phase 2 is advantageously characterized in that it is in the form of an aqueous or aqueous-alcoholic solution, or an anhydrous preparation.
• phase 1 and phase 2 can also be added to deodorants.
• the usual cosmetic deodorants are based on different active principles.
• antimicrobial substances as cosmetic deodorants, the bacterial flora on the skin can be reduced.
• only the odor causing microorganisms should be effectively reduced.
• the sweat flow itself is not affected, in the ideal case, only the microbial decomposition of the sweat is temporarily stopped.
• the combination of astringents with antimicrobial substances in one and the same composition is also common.
• odor maskers such as the common perfume ingredients
• odor absorbers for example the phyllosilicates described in DE 40 09 347, of these in particular montmorillonite, kaolinite, mit, beidellite, nontronite, saponite, hectorite, bentonite, smectite , Further, for example, zinc salts of ricinoleic acid.
• Germ-inhibiting agents are also suitable for incorporation into the preparations according to the invention.
• Advantageous substances are, for example, 2,4,4'-trichloro-2'-hydroxydiphenyl ether (Irgasan), 1, 6-di- (4-chlorphenylbiguanido) hexane (Chlorhexidine), 3,4,4'-trichlorocarbanilide, quaternary ammonium compounds, clove oil, mint oil, thyme oil, triethyl citrate, farnesol (3,7,1,1-trimethyl-2, 6,10-dodecatriene-1-ol),
• phase 1 and / or phase 2 also contain polymers.
• the polymers preferably originate from the range of celluloses and / or polystyrenes. They are advantageously hydrophobic or hydrophilic modified. They serve to adjust the viscosity of the phases and facilitate the pumpability and miscibility, as well as the drain or
• Usable polymers therefore include celluloses, polystyrenes and / or alkyl-acrylic
• Crosspolymers and may optionally be added to the NPK preparations.
• phase 1 and 2 of the product according to the invention in addition to water, ethanol and isopropanol, glycerol and propylene glycol skin-care fat or fat-like substances and oils such as oleic acid, cetyl alcohol,
• slime-forming and film-forming substances and thickening agents e.g. Hydroxyethyl or hydroxypropyl cellulose, polyacrylic acid, polyvinylpyrrolidone and waxes.
• phase 2 preparations which can be used according to the invention:
• Glucosides propylene glycol isostearates, glycol stearates), glyceryl isostearates), sorbitan
• Glucosides PEG-8 Oleates, Polyglyceryl-3 Methyglucose Distearates, PG-10 Stearates, Oleth-10, Oleth-10 / Polyoxyl 10 Oleyl Ether NF, Ceteth-10, PEG-8 Laurate, Ceteareth-12, Cocamide MEA, Polysorbate 60 NF, Polysorbate 60, PEG-40 Hydrogenated Castor Oil, Polysorbate 80, Isosteareth-20, PEG-60 Almond Glycerides, Polysorbate 80 NF, PEG-150 Laurate, PEG-20 Methyl Glucose Sesquistearate, Ceteareth-20, Oleth-20, Steareth -20, steareth-21, ceteth-20, isoceteth-20, PEG-30 glyceryl laurate, polysorbate 20, polysorbate 20 NF, laureth-23, PEG-100 stearate, steareth-100, PEG-80 sorbitan laur
• glyceryl isostearates Preference is given to using glyceryl isostearates, glyceryl stearates, steareth-2, ceteareth-20, steareth-21, PEG-40 hydrogenated castor oil, PG-10 stearates, isoceteth-20, isosteareth-20 and ceteareth-12.
• solubilizers are also known as solubilizers, but useful as emulsifiers for the Phase 2 preparations of this invention.
• PEG-40 Hydrogenated Castor Oil, Polysorbate 80, Laureth-23, PEG-150 Laurate and PEG-30 Glyceryl Laurate are further preferred.
• suitable cationic emulsifiers are from the group Cetrimonium Chloride, Palmitamidopropyltrimonium Chloride, Quaternium-87, Behentrimonium Chloride, Distearoylethyl Dimonium Chloride, Distearyldimonium Chloride, Stearamidopropyl
• Dimethylamine and / or Behentrimonium methosulfate Dimethylamine and / or Behentrimonium methosulfate.
• antioxidants which are suitable or customary for cosmetic and / or dermatological applications can be used as favorable antioxidants.
• the amount of antioxidants (one or more compounds) in the preparations is preferably from 0.001 to 30% by weight, particularly preferably from 0.05 to 20% by weight, in particular from 1 to 10% by weight, based on the total weight of the preparation . If the cosmetic or dermatological preparation of phase 2 is a solution or emulsion or dispersion, may be used as a solvent, bodying agent and / or
• Oils such as triglycerides of capric or caprylic and alkyl benzoate, but preferably cyclic silicone oils or volatile hydrocarbons;
• esters of fatty acids with lower C-number alcohols e.g. with isopropanol, propylene glycol or glycerol, or esters of fatty alcohols with alkanoic acids low C number or with
• Vegetable oils such as e.g. Avocado oil, meadowfoam seed oil, olive oil, sunflower oil, rapeseed oil, almond oil, evening primrose oil, coconut oil. Palm oil, linseed oil, shea butter.
• Skin care substances such as Panthenol, allantoin, urea, urea derivatives, guanidine, ascorbic acid, glyceryl glucose.
• mixtures of the above ingredients are used.
• water can be another ingredient.
• Suitable propellants for sprayable from aerosol containers cosmetic and / or dermatological preparations in the context of the present invention the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone or in mixture with each other. Also, the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone or in mixture with each other. Also, hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone or in mixture with each other. Also, the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone or in mixture with each other. Also, the usual known volatile, liquefied propellants, such as hydrocarbons (propane, butane, isobutane) are suitable, which can be used alone
• Dimethyl ether, nitrous oxide, carbon dioxide, nitrogen and compressed air are advantageous to use.
• oils are often added, which are miscible in the drug solution with the propellant gas (propane, butane, isobutane), as an oil that is immiscible, too
• Phase 2 cosmetic preparations can also be in the form of gels which, in addition to an effective content of the active ingredient according to the invention and solvents customarily used for this purpose, preferably water, are also organic thickeners (thickeners), eg Tamarind flour, konjakmannan, guar gum, hydroxypropyl guar, locust bean gum, gum arabic, xanthan gum, sodium alginate, cellulose derivatives, preferably methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
• the thickener is included in the formulation, for example in an amount between 0, 1 and 40 wt .-%, preferably between 0.5 and 25 wt .-%.
• the numbers represent parts by weight, based on the total mass of the preparation.
• TAA Triethanolamine
• Water, demineralized 20 Phase 1 and Phase 2 may be in different proportions from the
• ratios of 10:90 to 90:10 can be predetermined by different pump volumes.
• the axillary sweat volume is determined gravimetrically by cotton pads are balanced in the sauna after a 15min sweat phase.
• the relative sweat reduction for the silica compared to the untreated area is 54, 1%.
• the efficacy is therefore at the level of 10% ACH (see table). sample baseline after application rel. Reduction significance

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Chemical & Material Sciences (AREA)
• Inorganic Chemistry (AREA)
• Dispersion Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Mechanical Engineering (AREA)
• Cosmetics (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=56372922

Family Applications (1)

Country Status (8)

Family Cites Families (39)

• 2015
  • 2015-07-27 DE DE102015214144.6A patent/DE102015214144A1/de not_active Withdrawn
• 2016
  • 2016-07-11 CN CN201680043721.8A patent/CN107847771A/zh active Pending
  • 2016-07-11 EP EP16736495.9A patent/EP3328503A1/de not_active Ceased
  • 2016-07-11 AU AU2016299198A patent/AU2016299198A1/en not_active Abandoned
  • 2016-07-11 WO PCT/EP2016/066392 patent/WO2017016859A1/de active Application Filing
  • 2016-07-11 US US15/746,842 patent/US20180228705A1/en not_active Abandoned
  • 2016-07-11 BR BR112018001778A patent/BR112018001778A2/pt not_active Application Discontinuation
  • 2016-07-11 JP JP2018504215A patent/JP2018521102A/ja active Pending

Also Published As

Similar Documents

Legal Events